Login / Signup

Translational Modeling Identifies Synergy between Nanoparticle-Delivered miRNA-22 and Standard-of-Care Drugs in Triple-Negative Breast Cancer.

Prashant DograJavier Ruiz RamírezJoseph D ButnerMaria J PeláezCaroline ChungAnupama Hooda-NehraRenata PasqualiniWadih ArapVittorio CristiniGeorge A CalinBulent OzpolatZhihui Wang
Published in: Pharmaceutical research (2022)
Our analysis revealed the dose-response relationship, suggested optimal treatment frequency for miRNA-22 nanotherapy, and highlighted key determinants of therapy response, from which combination with immune checkpoint inhibitors was identified as a candidate strategy for improving treatment outcomes. More importantly, drug synergy was identified between miRNA-22 and standard-of-care drugs against TNBC, providing a basis for rational therapeutic combinations for improved response CONCLUSIONS: The present study highlights the translational potential of miRNA-22 nanotherapy for TNBC in combination with standard-of-care drugs.
Keyphrases
  • healthcare
  • palliative care
  • quality improvement
  • pain management
  • gene expression
  • single cell
  • risk assessment
  • chronic pain
  • bone marrow
  • cell therapy
  • adverse drug
  • electronic health record